login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
REVELATION BIOSC -CW27 (REVBW) Stock News
USA
- NASDAQ:REVBW -
0.0095
USD
0 (0%)
Last: 11/7/2025, 8:13:59 PM
Overview
Stock Chart
Technical Analysis
News
REVBW Latest News, Press Relases and Analysis
All
Press Releases
5 months ago - By: Yahoo Finance
- Mentions:
USFD
SCVL
NVDA
CRM
...
US Foods Seeing Inflows
5 months ago - By: Yahoo Finance
- Mentions:
REVB
1456
URBN
KSS
...
S&P lowers outlook on Volvo Cars rating citing US tariffs, competition in China
5 months ago - By: Yahoo Finance
- Mentions:
URBN
1456
Urban Outfitters Seeing Inflows
5 months ago - By: Yahoo Finance
- Mentions:
1456
URBN
KSS
Iron ore pessimism subsides despite looming Simandou supply
5 months ago - By: Yahoo Finance
- Mentions:
1456
URBN
IBKR
ZK
Morning Bid: Tariffs return along with capital tax fears
5 months ago - By: Yahoo Finance
- Mentions:
CADL
PFE
VREX
CTKB
...
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer
5 months ago - By: Yahoo Finance
- Mentions:
CTKB
MS
PFGC
CRM
...
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System
5 months ago - By: Yahoo Finance
- Mentions:
CRM
INFA
DELL
DHI
...
Bernstein Raises Salesforce (CRM) Price Target to $255, Keeps Underperform Rating
5 months ago - By: Yahoo Finance
- Mentions:
REVB
ESLT
CTKB
KROS
...
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering
5 months ago - By: Yahoo Finance
- Mentions:
MS
CRM
INFA
WFC
...
Morgan Stanley Lifts Salesforce, Inc. (CRM)’s Price Target to $404, Maintains Overweight Rating
5 months ago - By: Yahoo Finance
- Mentions:
ESLT
CRM
UNH
DHI
...
Elbit Systems Ltd. (ESLT) Secures $330M in Naval Defense Contracts
5 months ago - By: Yahoo Finance
- Mentions:
VREX
CTKB
KROS
CADL
...
Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy
7 months ago - By: Yahoo Finance
- Mentions:
REVB
TSLA
Why Revelation Biosciences Inc. (REVB) Went Down On Thursday?
3 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
3 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
3 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
3 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
3 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
3 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress
4 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
4 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection
4 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
4 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
Revelation Biosciences Raises $7.76 Million in Equity Financing
4 years ago - By: Revelation Biosciences, Inc.
- Mentions:
REVB
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
Please enable JavaScript to continue using this application.